TESTING试验二次分析:预测IgA肾病患者对糖皮质激素的个体化反应
该研究基于TESTING试验队列,构建模型预测IgA肾病患者对甲泼尼龙的个体化绝对风险降低(ARR)。模型纳入eGFR、年龄、蛋白尿等变量,预测ARR变异大(-10%至40%),预测ARR>10%者实际获益更大,且选择性治疗策略优于随机分配。
要点
- 预测ARR>10%的患者从甲泼尼龙治疗中获益更明显(ARR 24% vs -5%)。
- 个体化预测ARR变异范围大(-10%至40%),平均ARR为16.1%。
- 选择性治疗策略的受限平均生存时间优于随机分配(1194 vs 1028天)。
核心结论
- 模型可预测IgA肾病患者对甲泼尼龙的个体化反应,有助于将激素精准用于最可能获益者。
研究设计与样本
- TESTING试验的二次分析,纳入483例IgA肾病患者,中位随访43个月,评估至主要结局的时间。
主要发现
- 176/483例发生主要结局;预测ARR个体间变异大(-10%至40%),平均ARR为16.1%。
- 预测ARR>10%者观察到的ARR为24%,预测ARR≤10%者为-5%。
- 选择性治疗策略的RMST为1194天,随机分配为1028天;获益C-statistic为0.63(95%CI 0.56-0.70)。
- 不良事件频率在各ARR三分位间相似。
关键数值与推荐
- 治疗效应修饰变量包括eGFR、年龄、蛋白尿、RAS阻断剂剂量、种族、活检至入组时间、收缩压、性别、BMI、MEST-C T评分和C评分。
临床怎么用
- 临床可依据模型预测的ARR筛选最可能从甲泼尼龙获益的IgA肾病患者,实现个体化治疗。
局限性
- 本文为二次分析,模型区分度中等(C-statistic 0.63),外部验证需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Corticosteroids are effective for treating IgA nephropathy but have important adverse effects. In this secondary analysis of the TESTING cohort, we generated a model to predict, for an individual patient, the probability that they will respond to corticosteroids. METHODS: Time to the primary outcome (40% reduction in eGFR, kidney failure or death due to kidney disease) was evaluated in a Cox proportional hazards model including all potential treatment modifiers as main effects. Selected variables were forced into a model with treatment exposure and interaction terms between treatment and each included variable. The predicted four-year absolute risk of the primary outcome was generated for every patient individually under separate scenarios of being treated with methylprednisolone or placebo. The difference between the two scenarios was the predicted individual treatment effect on absolute risk reduction (ARR). Model performance was assessed using discrimination plots, restricted mean survival time (RMST) and the C-statistic for benefit. RESULTS: During a median of 43 months follow-up, 176 of 483 participants experienced the primary outcome. Selected treatment modifiers were eGFR, age, proteinuria, renin-angiotensin-aldosterone-system blockade dose, ethnicity, time from biopsy to enrollment, systolic blood pressure, sex, body mass index, and MEST-C T-score and C-score. Compared to the average ARR associated with methylprednisolone (16.1%), the predicted individual-level ARR was highly variable (-10% to 40%). Patients with predicted ARR over 10% had greater observed benefit from methylprednisolone (ARR 24%) versus those with predicted ARR 10% or less (observed ARR -5%). A policy of treating only patients with higher anticipated benefit had a longer RMST than using random treatment allocation (1,194 v 1,028 days). The C-statistic for benefit was 0.63 (95% confidence interval 0.56-0.70). The frequency of adverse events was similar across tertiles of ARR. CONCLUSIONS: We have generated a model that can predict individual patient response to methylprednisolone so that corticosteroids can be targeted to those most likely to benefit.
引用
- Canney M, Shan S, Er L, et al. A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy. Kidney Int. 2026. PMID: 41571096. doi:10.1016/j.kint.2025.12.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。